Publications
Detailed Information
Swedish amyloid precursor protein mutation increases phosphorylation of eIF2alpha in vitro and in vivo
Cited 36 time in
Web of Science
Cited 34 time in Scopus
- Authors
- Issue Date
- 2007
- Publisher
- Wiley-Blackwell
- Citation
- J Neurosci Res 85:1528-1537
- Keywords
- Alzheimer Disease/*metabolism ; Amyloid beta-Protein Precursor/genetics/*metabolism ; Animals ; Case-Control Studies ; Cell Death/physiology ; Cell Line ; Cerebral Cortex/cytology/*metabolism ; Eukaryotic Initiation Factor-2/*metabolism ; Gene Expression Regulation/physiology ; Humans ; Immunohistochemistry ; Matched-Pair Analysis ; Mice ; Mice, Transgenic ; Mutation ; Neurons/*metabolism ; Phosphorylation ; Rats ; Rats, Sprague-Dawley ; Reactive Oxygen Species/*metabolism ; Transfection ; Vitamin E/metabolism
- Abstract
- Swedish double mutation (KM670/671NL) of amyloid precursor protein (Swe-APP), a prevailing cause of familial Alzheimer's disease (FAD), is known to increase in Abeta production both in vitro and in vivo, but its underlying molecular basis leading to Alzheimer's disease (AD) pathogenesis remains to be elucidated, especially for the early phase of disease. We have confirmed initially that the expression of Swe-APP mutant transgene reduced cell viability via ROS production but this effect was eliminated by an anti-oxidative agent, vitamin E. We also found that eukaryotic translation initiation factor-2alpha (eIF2alpha), which facilitates binding of initiator tRNA to ribosomes to set on protein synthesis, was phosphorylated in cultured cells expressing Swe-APP. This increase in phosphorylated eIF2alpha was also attenuated significantly by treatment with vitamin E. The finding that eIF2alpha became highly phosphorylated by increased production of Abeta was substantiated in brain tissues of both an AD animal model and AD patients. Although an increase in Abeta production would result in cell death eventually (in late-phase of the disease), the altered phosphorylation state of eIF2alpha evoked by Abeta may account for the decreased efficacy of mRNA translation and de novo protein synthesis required for synaptic plasticity, and may consequently be one of molecular causes for impairment of cognitive functions exhibited in the early phase of AD patients.
- ISSN
- 0360-4012 (Print)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17393484
https://hdl.handle.net/10371/23498
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.